The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Intersection · Compounds × observational data

Compounds topics tagged observational data

Topics in Compounds carrying the tag observational data. Cohort, registry and claims data, with the confounding that comes with it.

33 topics

TopicParticipantsRepliesViewsActivity
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion
On the subject in the title: GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Working notes rather than a conclusion. I have seen STEP 2 ( Lancet , 2021) cited in support of…
PPNKRVHBMM+47 53 6.9k 2h
Reading a rodent study on a secretagogue without over-extrapolating — the long version
Reading a rodent study on a secretagogue without over-extrapolating — the long version — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support…
CDDBANKBMA+59 66 30k 4h
Stability of BPC-157 in solution: what has been measured — one year on
On the subject in the title: Stability of BPC-157 in solution: what has been measured — one year on Working notes rather than a conclusion. Comparing STEP 2 ( Lancet , 2021) with STEP 1 ( N Engl J Med , 2021)…
KFNASCPWVB+84 98 7.8k 18h
Publication patterns in the BPC-157 literature, examined
Posting this under the heading it deserves: Publication patterns in the BPC-157 literature, examined Everything below is what sits behind that. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in support of…
MMMHEIDVBO+40 45 3.4k 21h
Tesamorelin has an approved indication — what that changes about the evidence
Tesamorelin has an approved indication — what that changes about the evidence — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SURMOUNT-1 ( N Engl J…
FHPMOONBPW+23 27 3.4k 1d
BPC-157: what the rodent literature actually shows, and what it does not — does this still hold?
The question in the title: BPC-157: what the rodent literature actually shows, and what it does not — does this still hold? I will give what I have already checked below so nobody repeats it. I have seen…
ASBSMCSBLS+6 10 3.1k 1d
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people admit
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people admit Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURPASS-4 ( Lancet ,…
FAKLSLAS+50 55 7.8k 2d
Evidence quality in the secretagogue literature: an honest assessment
Evidence quality in the secretagogue literature: an honest assessment Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURMOUNT-OSA ( N Engl J Med , 2024) with STEP…
SSSVK 2 25k 9d
Secretagogues and glucose tolerance: the mechanistic concern
On the subject in the title: Secretagogues and glucose tolerance: the mechanistic concern Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…
INRDMDOVFF+64 70 52k 17d
Why this subcategory is stricter about sourcing than most
Asking directly, because I could not find a straight answer: Why this subcategory is stricter about sourcing than most Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before posting; the…
DOCAEFRESC+48 52 617 21d
Stability of BPC-157 in solution: what has been measured
Stability of BPC-157 in solution: what has been measured — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with FLOW ( N Engl J Med , 2024) and finding the…
AKEFSS 2 805 30d
Secretagogues and glucose tolerance: the mechanistic concern — what changed since
Secretagogues and glucose tolerance: the mechanistic concern — what changed since Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021)…
TLDKAIEF+2 6 31k 2mo
[2026 update] Publication patterns in the BPC-157 literature, examined
Publication patterns in the BPC-157 literature, examined Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med , 2024). Please read it…
IGPTEARSI+15 19 11k 4mo
IGF-1 as a surrogate endpoint and its limitations
IGF-1 as a surrogate endpoint and its limitations Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I do not…
OCSLTDCJN+5 9 35k 4mo
Oral versus injected administration claims for BPC-157
Oral versus injected administration claims for BPC-157 — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think…
RMAAMMRST+20 24 47k 4mo
Reading a preclinical wound-healing model and its relevance to a human tendon — a second dataset
Reading a preclinical wound-healing model and its relevance to a human tendon — a second dataset — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016)…
RDSTGBTNAA+64 69 27k 4mo
CJC-1295 with and without DAC: what the modification does — what changed since
CJC-1295 with and without DAC: what the modification does — what changed since Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURMOUNT-OSA ( N Engl J Med , 2024)…
SSCDSBGHNN 4 5.1k 7mo
Reading a rodent study on a secretagogue without over-extrapolating
Posting this under the heading it deserves: Reading a rodent study on a secretagogue without over-extrapolating Everything below is what sits behind that. I have seen STEP 8 ( JAMA , 2022) cited in support of…
EKLLTVOF+50 54 32k 10mo
BPC-157: what the rodent literature actually shows, and what it does not
BPC-157: what the rodent literature actually shows, and what it does not — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a…
PILSTMIAK+44 48 3k 10mo
Analytical identity of BPC-157: a 15-mer with a simple mass
Analytical identity of BPC-157: a 15-mer with a simple mass Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURMOUNT-OSA ( N Engl J Med , 2024) with STEP 2 (…
MRFNLVWPII+3 7 5.2k 10mo
Second pass at: Why this subcategory is stricter about sourcing than most
Second pass at: Why this subcategory is stricter about sourcing than most — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SURMOUNT-4 ( JAMA ,…
AWGHTVCDAS+120 129 61k 11mo
TB-500 and thymosin beta-4: the fragment versus the protein
TB-500 and thymosin beta-4: the fragment versus the protein Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a…
COGDJLDVS+107 118 22k 11mo
BPC-157: what the rodent literature actually shows, and what it does not — a second dataset
On the subject in the title: BPC-157: what the rodent literature actually shows, and what it does not — a second dataset Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019)…
WNCDSOOSB+77 84 54k 11mo
IGF-1 as a surrogate endpoint and its limitations — the long version
On the subject in the title: IGF-1 as a surrogate endpoint and its limitations — the long version Working notes rather than a conclusion. I have seen STEP 2 ( Lancet , 2021) cited in support of a claim I do…
NOMGCRKBGP+14 18 53k 12mo
About the Repair & healing peptides category
BPC-157, TB-500 and similar. Mostly preclinical evidence; this subcategory is strict about not overstating it. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit…
SLHSENALEF 4 19k 13mo
Why plausible mechanism is not evidence of effect
Asking directly, because I could not find a straight answer: Why plausible mechanism is not evidence of effect Session topic: STEP 2 ( Lancet , 2021). Please read it before posting; the discussion is much…
FYGFSPCNAK+14 18 57k 13mo
Follow-up: Tesamorelin has an approved indication — what that changes about the evidence
Posting this under the heading it deserves: Tesamorelin has an approved indication — what that changes about the evidence Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with…
RLHFTDIBBW+63 68 18k 14mo
Ipamorelin selectivity claims and where they came from — a second dataset
Posting this under the heading it deserves: Ipamorelin selectivity claims and where they came from — a second dataset Everything below is what sits behind that. I have seen SURPASS-2 ( N Engl J Med , 2021)…
TIDCM 2 27k 14mo
Revisiting: Oral versus injected administration claims for BPC-157
On the subject in the title: Revisiting: Oral versus injected administration claims for BPC-157 Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a claim I…
IGAAILRILD+23 27 7.7k 15mo
Revisiting: What a well-designed human trial of a secretagogue would look like
On the subject in the title: Revisiting: What a well-designed human trial of a secretagogue would look like Working notes rather than a conclusion. Session topic: SELECT ( N Engl J Med , 2023). Please read it…
HBSBOIDAS+69 74 25k 18mo